<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36131342</PMID><DateCompleted><Year>2022</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1475-2840</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>21</Day></PubDate></JournalIssue><Title>Cardiovascular diabetology</Title><ISOAbbreviation>Cardiovasc Diabetol</ISOAbbreviation></Journal><ArticleTitle>Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system.</ArticleTitle><Pagination><StartPage>190</StartPage><MedlinePgn>190</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">190</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12933-022-01623-4</ELocationID><Abstract><AbstractText Label="BACKGROUND">Post-acute sequelae of COVID-19 (PASC), also now known as long COVID, has become a major global health and economic burden. Previously, we provided evidence that there is a significant insoluble fibrin amyloid microclot load in the circulation of individuals with long COVID, and that these microclots entrap a substantial number of inflammatory molecules, including those that might prevent clot breakdown. Scientifically, the most challenging aspect of this debilitating condition is that traditional pathology tests such as a serum CRP (C-reactive protein) may not show any significant abnormal inflammatory markers, albeit these tests measure only the soluble inflammatory molecules. Elevated, or abnormal soluble biomarkers such as IL-6, D-Dimer or fibrinogen indicate an increased risk for thrombosis or a host immune response in COVID-19. The absence of biomarkers in standard pathology tests, result in a significant amount of confusion for patients and clinicians, as patients are extremely sick or even bed-ridden but with no regular identifiable reason for their disease. Biomarkers that are currently available cannot detect the molecules present in the microclots we identified and are therefore unable to confirm their presence or the mechanisms that drive their formation.</AbstractText><AbstractText Label="METHODS">Here we analysed the protein content of double-digested microclots of 99 long COVID patients and 29 healthy controls. The patients suffering from long COVID reported their symptoms through a questionnaire completed by themselves or their attending physician.</AbstractText><AbstractText Label="RESULTS">Our long COVID cohort's symptoms were found to be in line with global findings, where the most prevalent symptoms were constant fatigue (74%,) cognitive impairment (71%) and depression and anxiety (30%). Our most noteworthy findings were a reduced level of plasma&#xa0;Kallikrein compared to our controls, an increased level of platelet factor 4 (PF4) von Willebrand factor (VWF), and a marginally increased level of &#x3b1;-2 antiplasmin (&#x3b1;-2-AP). We also found a significant presence of antibodies entrapped inside these microclots.</AbstractText><AbstractText Label="CONCLUSION">Our results confirm the presence of pro-inflammatory molecules that may also contribute to a failed fibrinolysis phenomenon, which could possibly explain why individuals with long COVID suffer from chronic fatigue, dyspnoea, or cognitive impairment. In addition, significant platelet hyperactivation was noted. Hyperactivation will result in the granular content of platelets being shed into the circulation, including PF4. Overall, our results provide further evidence of both a failed fibrinolytic system in long COVID/PASC and the entrapment of many proteins whose presence might otherwise go unrecorded. These findings might have significant implications for individuals with pre-existing comorbidities, including cardiovascular disease and type 2 diabetes.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kruger</LastName><ForeName>Arneaux</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Private Bag X1 Matieland, Stellenbosch, 7602, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vlok</LastName><ForeName>Mare</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Central Analytical Facility, Mass Spectrometry Stellenbosch University, Tygerberg Campus, Room 6054, Clinical Building, Francie Van Zijl Drive, Tygerberg, Cape Town, 7505, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Private Bag X1 Matieland, Stellenbosch, 7602, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Venter</LastName><ForeName>Chantelle</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Private Bag X1 Matieland, Stellenbosch, 7602, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laubscher</LastName><ForeName>Gert Jacobus</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Mediclinic Stellenbosch, Stellenbosch, 7600, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kell</LastName><ForeName>Douglas B</ForeName><Initials>DB</Initials><Identifier Source="ORCID">0000-0001-5838-7963</Identifier><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Private Bag X1 Matieland, Stellenbosch, 7602, South Africa. dbk@liv.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, L69 7ZB, UK. dbk@liv.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Novo Nordisk Foundation Centre for Biosustainability, Technical University of Denmark, Kemitorvet 200, 2800, Kongens Lyngby, Denmark. dbk@liv.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pretorius</LastName><ForeName>Etheresia</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9108-2384</Identifier><AffiliationInfo><Affiliation>Department of Physiological Sciences, Faculty of Science, Stellenbosch University, Private Bag X1 Matieland, Stellenbosch, 7602, South Africa. resiap@sun.ac.za.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry and Systems Biology, Institute of Systems, Molecular and Integrative Biology, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, L69 7ZB, UK. resiap@sun.ac.za.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cardiovasc Diabetol</MedlineTA><NlmUniqueID>101147637</NlmUniqueID><ISSNLinking>1475-2840</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000979">alpha-2-Antiplasmin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014841">von Willebrand Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>37270-94-3</RegistryNumber><NameOfSubstance UI="D010978">Platelet Factor 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>9001-31-4</RegistryNumber><NameOfSubstance UI="D005337">Fibrin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9001-32-5</RegistryNumber><NameOfSubstance UI="D005340">Fibrinogen</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.34</RegistryNumber><NameOfSubstance UI="D020842">Plasma Kallikrein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005337" MajorTopicYN="N">Fibrin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005340" MajorTopicYN="N">Fibrinogen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020842" MajorTopicYN="N">Plasma Kallikrein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010978" MajorTopicYN="N">Platelet Factor 4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="N">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000979" MajorTopicYN="N">alpha-2-Antiplasmin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014841" MajorTopicYN="N">von Willebrand Factor</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibodies</Keyword><Keyword MajorTopicYN="N">Failed fibrinolysis</Keyword><Keyword MajorTopicYN="N">Kallikrein</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Microclots</Keyword><Keyword MajorTopicYN="N">Platelet factor 4</Keyword><Keyword MajorTopicYN="N">Platelet hyperactivation</Keyword><Keyword MajorTopicYN="N">von Willebrand factor</Keyword></KeywordList><CoiStatement>EP is the managing director of BioCODE Technologies.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>21</Day><Hour>23</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36131342</ArticleId><ArticleId IdType="pmc">PMC9491257</ArticleId><ArticleId IdType="doi">10.1186/s12933-022-01623-4</ArticleId><ArticleId IdType="pii">10.1186/s12933-022-01623-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pretorius E, Vlok M, Venter C, Bezuidenhout JA, Laubscher GJ, Steenkamp J, Kell DB. Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20(1):172. doi: 10.1186/s12933-021-01359-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01359-7</ArticleId><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of 1 biological factors that may contribute to persistent symptoms. Front Microbiol. 2021 doi: 10.3389/fmicb.2021.698169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Deer RR, Rock MA, Vasilevsky N, Carmody L, Rando H, Anzalone AJ, Basson MD, Bennett TD, Bergquist T, Boudreau EA, et al. Characterizing long COVID: deep phenotype of a complex condition. EBioMedicine. 2021;74:103722. doi: 10.1016/j.ebiom.2021.103722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103722</ArticleId><ArticleId IdType="pmc">PMC8613500</ArticleId><ArticleId IdType="pubmed">34839263</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, Redfield S, Austin JP, Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631&#x2013;637. doi: 10.1002/path.1570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1570</ArticleId><ArticleId IdType="pmc">PMC7167720</ArticleId><ArticleId IdType="pubmed">15141377</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D, Han Z, Oppenheim JJ. Alarmins and immunity. Immunol Rev. 2017;280(1):41&#x2013;56. doi: 10.1111/imr.12577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12577</ArticleId><ArticleId IdType="pmc">PMC5699517</ArticleId><ArticleId IdType="pubmed">29027222</ArticleId></ArticleIdList></Reference><Reference><Citation>Giani M, Seminati D, Lucchini A, Foti G, Pagni F. Exuberant plasmocytosis in bronchoalveolar lavage specimen of the first patient requiring extracorporeal membrane oxygenation for SARS-CoV-2 in Europe. J Thorac Oncol. 2020;15(5):e65&#x2013;e66. doi: 10.1016/j.jtho.2020.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtho.2020.03.008</ArticleId><ArticleId IdType="pmc">PMC7118681</ArticleId><ArticleId IdType="pubmed">32194247</ArticleId></ArticleIdList></Reference><Reference><Citation>Monteleone G, Sarzi-Puttini PC, Ardizzone S. Preventing COVID-19-induced pneumonia with anticytokine therapy. Lancet Rheumatol. 2020;2(5):e255&#x2013;e256. doi: 10.1016/S2665-9913(20)30092-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30092-8</ArticleId><ArticleId IdType="pmc">PMC7193140</ArticleId><ArticleId IdType="pubmed">32368737</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciceri F, Beretta L, Scandroglio AM, Colombo S, Landoni G, Ruggeri A, Peccatori J, D'Angelo A, De Cobelli F, Rovere-Querini P, et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc. 2020;22(2):95&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10692450</ArticleId><ArticleId IdType="pubmed">32294809</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins V, Sohaei D, Diamandis EP, Prassas I. COVID-19: from an acute to chronic disease? Potential long-term health consequences. Crit Rev Clin Lab Sci. 2021;58(5):297&#x2013;310. doi: 10.1080/10408363.2020.1860895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408363.2020.1860895</ArticleId><ArticleId IdType="pubmed">33347790</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobler C, Maphumulo SC, Grobbelaar LM, Bredenkamp JC, Laubscher GJ, Lourens PJ, Steenkamp J, Kell DB, Pretorius E. Covid-19: the rollercoaster of fibrin(Ogen), D-Dimer, Von Willebrand Factor, P-selectin and their interactions with endothelial cells, platelets and erythrocytes. Int J Mol Sci. 2020 doi: 10.3390/ijms21145168.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21145168</ArticleId><ArticleId IdType="pmc">PMC7403995</ArticleId><ArticleId IdType="pubmed">32708334</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Venter C, Laubscher GJ, Lourens PJ, Steenkamp J, Kell DB. Prevalence of readily detected amyloid blood clots in 'unclotted' Type 2 Diabetes Mellitus and COVID-19 plasma: a preliminary report. Cardiovasc Diabetol. 2020;19(1):193. doi: 10.1186/s12933-020-01165-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-020-01165-7</ArticleId><ArticleId IdType="pmc">PMC7670290</ArticleId><ArticleId IdType="pubmed">33203441</ArticleId></ArticleIdList></Reference><Reference><Citation>Venter C, Bezuidenhout JA, Laubscher GJ, Lourens PJ, Steenkamp J, Kell DB, Pretorius E. Erythrocyte, platelet, serum ferritin, and P-selectin pathophysiology implicated in severe hypercoagulation and vascular complications in COVID-19. Int J Mol Sci. 2020 doi: 10.3390/ijms21218234.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21218234</ArticleId><ArticleId IdType="pmc">PMC7662625</ArticleId><ArticleId IdType="pubmed">33153161</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;rlinger K, Levy JH. COVID-19&#x2013;associated coagulopathy: less fibrinolysis can be more harmful! Anesthesiology. 2021;134(3):366&#x2013;369. doi: 10.1097/ALN.0000000000003688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0000000000003688</ArticleId><ArticleId IdType="pmc">PMC7864600</ArticleId><ArticleId IdType="pubmed">33417671</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P, L&#xfc;scher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020;41(32):3038&#x2013;3044. doi: 10.1093/eurheartj/ehaa623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa623</ArticleId><ArticleId IdType="pmc">PMC7470753</ArticleId><ArticleId IdType="pubmed">32882706</ArticleId></ArticleIdList></Reference><Reference><Citation>Wool GD, Miller JL. The impact of COVID-19 disease on platelets and coagulation. Pathobiology. 2021;88(1):15&#x2013;27. doi: 10.1159/000512007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000512007</ArticleId><ArticleId IdType="pmc">PMC7649697</ArticleId><ArticleId IdType="pubmed">33049751</ArticleId></ArticleIdList></Reference><Reference><Citation>Laubscher GJ, Lourens PJ, Venter C, Kell DB, Pretorius E. TEG&#xae;, microclot and platelet mapping for guiding early management of severe COVID-19 coagulopathy. J Clin Med. 2021 doi: 10.3390/jcm10225381.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10225381</ArticleId><ArticleId IdType="pmc">PMC8621180</ArticleId><ArticleId IdType="pubmed">34830660</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell DB, Pretorius E. Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. Prog Biophys Mol Biol. 2017;123:16&#x2013;41. doi: 10.1016/j.pbiomolbio.2016.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pbiomolbio.2016.08.006</ArticleId><ArticleId IdType="pubmed">27554450</ArticleId></ArticleIdList></Reference><Reference><Citation>Willyard C. Could tiny blood clots cause long COVID's puzzling symptoms? Nature. 2022;608(7924):662&#x2013;664. doi: 10.1038/d41586-022-02286-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-02286-7</ArticleId><ArticleId IdType="pubmed">36002482</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, F&#xfc;rst J, Schulze-Rothe S, Wallukat A, H&#xf6;nicke AS, M&#xfc;ller J. Functional autoantibodies against G-protein coupled receptors in patients with persistent long-COVID-19 symptoms. J Transl Autoimmun. 2021;4:100100. doi: 10.1016/j.jtauto.2021.100100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>NewsCAP: Autoantibody reactivity implicated in 'long' COVID-19. Am J Nurs 2021, 121(3):17.</Citation><ArticleIdList><ArticleId IdType="pubmed">33625001</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertin D, Kaphan E, Weber S, Babacci B, Arcani R, Faucher B, M&#xe9;nard A, Brodovitch A, Mege JL, Bardin N. Persistent IgG anticardiolipin autoantibodies are associated with post-COVID syndrome. Int J Infect Dis. 2021;113:23&#x2013;25. doi: 10.1016/j.ijid.2021.09.079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.09.079</ArticleId><ArticleId IdType="pmc">PMC8487460</ArticleId><ArticleId IdType="pubmed">34614444</ArticleId></ArticleIdList></Reference><Reference><Citation>https://assets.thermofisher.com/TFS-Assets/CMD/manuals/Man-4820-4103-UltiMate-3000-RSLCnano-Man48204103-EN.pdf.</Citation></Reference><Reference><Citation>https://assets.thermofisher.com/TFS-Assets/CMD/manuals/man-80000-97027-orbitrap-tribridseries-hardware-man8000097027-en.pdf.</Citation></Reference><Reference><Citation>Barsnes H, Vaudel M. SearchGUI: a highly adaptable common interface for proteomics search and de novo engines. J Proteome Res. 2018;17(7):2552&#x2013;2555. doi: 10.1021/acs.jproteome.8b00175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jproteome.8b00175</ArticleId><ArticleId IdType="pubmed">29774740</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigden DJ, Fern&#xe1;ndez XM. The 27th annual nucleic acids research database issue and molecular biology database collection. Nucleic Acids Res. 2020;48(D1):D1&#x2013;d8. doi: 10.1093/nar/gkz1161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz1161</ArticleId><ArticleId IdType="pmc">PMC6943072</ArticleId><ArticleId IdType="pubmed">31906604</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, Thomson GJA, Nunes JM, Engelbrecht AM, Nell TA, de Villiers WJS, de Beer MC, Engelbrecht L, Kell DB, Pretorius E. Serum amyloid A binds to fibrin(ogen), promoting fibrin amyloid formation. Sci Rep. 2019;9(1):3102. doi: 10.1038/s41598-019-39056-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-39056-x</ArticleId><ArticleId IdType="pmc">PMC6395759</ArticleId><ArticleId IdType="pubmed">30816210</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Mbotwe S, Kell DB. Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular co-morbidities. Sci Rep. 2017;7(1):9680. doi: 10.1038/s41598-017-09860-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-09860-4</ArticleId><ArticleId IdType="pmc">PMC5574907</ArticleId><ArticleId IdType="pubmed">28851981</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Page MJ, Engelbrecht L, Ellis GC, Kell DB. Substantial fibrin amyloidogenesis in type 2 diabetes assessed using amyloid-selective fluorescent stains. Cardiovasc Diabetol. 2017;16(1):141. doi: 10.1186/s12933-017-0624-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-017-0624-5</ArticleId><ArticleId IdType="pmc">PMC5668975</ArticleId><ArticleId IdType="pubmed">29096623</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Mbotwe S, Bester J, Robinson CJ, Kell DB. Acute induction of anomalous and amyloidogenic blood clotting by molecular amplification of highly substoichiometric levels of bacterial lipopolysaccharide. J R Soc Interface. 2016 doi: 10.1098/rsif.2016.0539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsif.2016.0539</ArticleId><ArticleId IdType="pmc">PMC5046953</ArticleId><ArticleId IdType="pubmed">27605168</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020; 20(8):e192&#x2013;e197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7292605</ArticleId><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamatopoulos K, Belessi C, Hadzidimitriou A, Smilevska T, Kalagiakou E, Hatzi K, Stavroyianni N, Athanasiadou A, Tsompanakou A, Papadaki T, et al. Immunoglobulin light chain repertoire in chronic lymphocytic leukemia. Blood. 2005;106(10):3575&#x2013;3583. doi: 10.1182/blood-2005-04-1511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2005-04-1511</ArticleId><ArticleId IdType="pubmed">16076869</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi R, Rassenti LZ, Meisenholder G, Carson DA, Kipps TJ. Autoantigen inhibits apoptosis of a human B cell leukemia that produces pathogenic rheumatoid factor. J Immunol. 1993;151(12):7273&#x2013;7283.</Citation><ArticleIdList><ArticleId IdType="pubmed">7505024</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Venter C, Laubscher GJ, Kotze MJ, Oladejo SO, Watson LR, Rajaratnam K, Watson BW, Kell DB. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). Cardiovasc Diabetol. 2022;21(1):148. 10.1186/s12933-022-01579-5. PMID: 35933347; PMCID: PMC9356426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9356426</ArticleId><ArticleId IdType="pubmed">35933347</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell DB, Laubscher GJ, Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochem J. 2022;479(4):537&#x2013;559. doi: 10.1042/BCJ20220016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20220016</ArticleId><ArticleId IdType="pmc">PMC8883497</ArticleId><ArticleId IdType="pubmed">35195253</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukherjee A, Morales-Scheihing D, Butler PC, Soto C. Type 2 diabetes as a protein misfolding disease. Trends Mol Med. 2015;21(7):439&#x2013;449. doi: 10.1016/j.molmed.2015.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2015.04.005</ArticleId><ArticleId IdType="pmc">PMC4492843</ArticleId><ArticleId IdType="pubmed">25998900</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, Pujol JC, Klaser K, Antonelli M, Canas LS, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C, Guijarro C, Torres-Macho J, Velasco-Arribas M, Plaza-Canteli S, Hern&#xe1;ndez-Barrera V, Arias-Naval&#xf3;n JA. Diabetes and the risk of long-term post-COVID symptoms. Diabetes. 2021;70(12):2917&#x2013;2921. doi: 10.2337/db21-0329.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db21-0329</ArticleId><ArticleId IdType="pubmed">34580087</ArticleId></ArticleIdList></Reference><Reference><Citation>Khunti K, Davies MJ, Kosiborod MN, Nauck MA. Long COVID&#x2014;metabolic risk factors and novel therapeutic management. Nat Rev Endocrinol. 2021;17(7):379&#x2013;380. doi: 10.1038/s41574-021-00495-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-021-00495-0</ArticleId><ArticleId IdType="pmc">PMC8054121</ArticleId><ArticleId IdType="pubmed">33875855</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, Li S, Hong S, Zhang R, Xie J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881&#x2013;895.e820. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Finer N, Garnett SP, Bruun JM. COVID-19 and obesity. Clin Obes. 2020;10(3):e12365. doi: 10.1111/cob.12365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cob.12365</ArticleId><ArticleId IdType="pmc">PMC7267455</ArticleId><ArticleId IdType="pubmed">32342637</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates T, Razieh C, Zaccardi F, Davies MJ, Khunti K. Obesity and risk of COVID-19: analysis of UK biobank. Prim Care Diabetes. 2020;14(5):566&#x2013;567. doi: 10.1016/j.pcd.2020.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcd.2020.05.011</ArticleId><ArticleId IdType="pmc">PMC7254007</ArticleId><ArticleId IdType="pubmed">32493608</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattar N, Ho FK, Gill JM, Ghouri N, Gray SR, Celis-Morales CA, Katikireddi SV, Berry C, Pell JP, McMurray JJ, et al. BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: preliminary findings from UK biobank. Diabetes Metab Syndr. 2020;14(5):1149&#x2013;1151. doi: 10.1016/j.dsx.2020.06.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.06.060</ArticleId><ArticleId IdType="pmc">PMC7326434</ArticleId><ArticleId IdType="pubmed">32668401</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerotziafas GT, Catalano M, Colgan MP, Pecsvarady Z, Wautrecht JC, Fazeli B, Olinic DM, Farkas K, Elalamy I, Falanga A, et al. Guidance for the management of patients with vascular disease or cardiovascular risk factors and COVID-19: position paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thromb Haemost. 2020;120(12):1597&#x2013;1628. doi: 10.1055/s-0040-1715798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1715798</ArticleId><ArticleId IdType="pmc">PMC7869052</ArticleId><ArticleId IdType="pubmed">32920811</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531&#x2013;538. doi: 10.1007/s00392-020-01626-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-020-01626-9</ArticleId><ArticleId IdType="pmc">PMC7087935</ArticleId><ArticleId IdType="pubmed">32161990</ArticleId></ArticleIdList></Reference><Reference><Citation>Malek AE, Raad II, Jabbour E. Cancer and COVID-19. Lancet. 2020;396(10257):1066&#x2013;1067. doi: 10.1016/S0140-6736(20)32070-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32070-5</ArticleId><ArticleId IdType="pmc">PMC7544468</ArticleId><ArticleId IdType="pubmed">33038963</ArticleId></ArticleIdList></Reference><Reference><Citation>Neri T, Nieri D, Celi A. P-selectin blockade in COVID-19-related ARDS. Am J Physiol Lung Cell Mol Physiol. 2020;318(6):L1237&#x2013;l1238. doi: 10.1152/ajplung.00202.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00202.2020</ArticleId><ArticleId IdType="pmc">PMC7276981</ArticleId><ArticleId IdType="pubmed">32464083</ArticleId></ArticleIdList></Reference><Reference><Citation>Coomes EA, Haghbayan H. Interleukin-6 in COVID-19: a systematic review and meta-analysis. Rev Med Virol. 2020;30(6):1&#x2013;9. doi: 10.1002/rmv.2141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2141</ArticleId><ArticleId IdType="pmc">PMC7460877</ArticleId><ArticleId IdType="pubmed">32845568</ArticleId></ArticleIdList></Reference><Reference><Citation>Rostami M, Mansouritorghabeh H. D-dimer level in COVID-19 infection: a systematic review. Expert Rev Hematol. 2020;13(11):1265&#x2013;1275. doi: 10.1080/17474086.2020.1831383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17474086.2020.1831383</ArticleId><ArticleId IdType="pubmed">32997543</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancellotti S, Sacco M, Basso M, De Cristofaro R. Mechanochemistry of von Willebrand factor. Biomol Concepts. 2019;10(1):194&#x2013;208. doi: 10.1515/bmc-2019-0022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/bmc-2019-0022</ArticleId><ArticleId IdType="pubmed">31778361</ArticleId></ArticleIdList></Reference><Reference><Citation>Nevzorova TA, Mordakhanova ER, Daminova AG, Ponomareva AA, Andrianova IA, Le Minh G, Rauova L, Litvinov RI, Weisel JW. Platelet factor 4-containing immune complexes induce platelet activation followed by calpain-dependent platelet death. Cell Death Discov. 2019;5:106. doi: 10.1038/s41420-019-0188-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-019-0188-0</ArticleId><ArticleId IdType="pmc">PMC6591288</ArticleId><ArticleId IdType="pubmed">31263574</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodard J, Kremer Hovinga JA, Fontana P, Studt JD, Gruel Y, Greinacher A. COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies. J Thromb Haemost. 2021;19(5):1294&#x2013;1298. doi: 10.1111/jth.15262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15262</ArticleId><ArticleId IdType="pmc">PMC8013750</ArticleId><ArticleId IdType="pubmed">33550713</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston I, Sarkar A, Hayes V, Koma GT, Arepally GM, Chen J, Chung DW, L&#xf3;pez JA, Cines DB, Rauova L, et al. Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contributes to thrombus propagation. Blood. 2020;135(15):1270&#x2013;1280. doi: 10.1182/blood.2018881607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2018881607</ArticleId><ArticleId IdType="pmc">PMC7146020</ArticleId><ArticleId IdType="pubmed">32077913</ArticleId></ArticleIdList></Reference><Reference><Citation>Oronsky B, Larson C, Hammond TC, Oronsky A, Kesari S, Lybeck M, Reid TR. A review of persistent post-COVID syndrome (PPCS) Clin Rev Allergy Immunol. 2021 doi: 10.1007/s12016-021-08848-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-021-08848-3</ArticleId><ArticleId IdType="pmc">PMC7896544</ArticleId><ArticleId IdType="pubmed">33609255</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol. 2021;12:698169. doi: 10.3389/fmicb.2021.698169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Kang Y, Chang J, Song J, Kim BK. Determination of serotonin concentration in single human platelets through single-entity electrochemistry. ACS Sens. 2020;5(7):1943&#x2013;1948. doi: 10.1021/acssensors.0c00267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acssensors.0c00267</ArticleId><ArticleId IdType="pubmed">32498511</ArticleId></ArticleIdList></Reference><Reference><Citation>Cloutier N, Allaeys I, Marcoux G, Machlus KR, Mailhot B, Zufferey A, Levesque T, Becker Y, Tessandier N, Melki I, et al. Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration. Proc Natl Acad Sci U S A. 2018;115(7):E1550&#x2013;e1559. doi: 10.1073/pnas.1720553115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1720553115</ArticleId><ArticleId IdType="pmc">PMC5816207</ArticleId><ArticleId IdType="pubmed">29386381</ArticleId></ArticleIdList></Reference><Reference><Citation>Keyes SR, Rudnick G. Coupling of transmembrane proton gradients to platelet serotonin transport. J Biol Chem. 1982;257(3):1172&#x2013;1176. doi: 10.1016/S0021-9258(19)68170-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(19)68170-6</ArticleId><ArticleId IdType="pubmed">7056713</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesch KP, Wolozin BL, Murphy DL, Reiderer P. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. J Neurochem. 1993;60(6):2319&#x2013;2322. doi: 10.1111/j.1471-4159.1993.tb03522.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1993.tb03522.x</ArticleId><ArticleId IdType="pubmed">7684072</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Z, Li Z, Shao Y, Liao C. Discovery and development of plasma kallikrein inhibitors for multiple diseases. Eur J Med Chem. 2020;190:112137. doi: 10.1016/j.ejmech.2020.112137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2020.112137</ArticleId><ArticleId IdType="pubmed">32066009</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofman Z, de Maat S, Hack CE, Maas C. Bradykinin: inflammatory product of the coagulation system. Clin Rev Allergy Immunol. 2016;51(2):152&#x2013;161. doi: 10.1007/s12016-016-8540-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-016-8540-0</ArticleId><ArticleId IdType="pmc">PMC5025506</ArticleId><ArticleId IdType="pubmed">27122021</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstock LB, Brook JB, Walters AS, Goris A, Afrin LB, Molderings GJ. Mast cell activation symptoms are prevalent in long-COVID. Int J Infect Dis. 2021;112:217&#x2013;226. doi: 10.1016/j.ijid.2021.09.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.09.043</ArticleId><ArticleId IdType="pmc">PMC8459548</ArticleId><ArticleId IdType="pubmed">34563706</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolte D, Shariat-Madar Z. Plasma Kallikrein inhibitors in cardiovascular disease: an innovative therapeutic approach. Cardiol Rev. 2016;24(3):99&#x2013;109. doi: 10.1097/CRD.0000000000000069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CRD.0000000000000069</ArticleId><ArticleId IdType="pubmed">25853524</ArticleId></ArticleIdList></Reference><Reference><Citation>Loimaranta V, Hepojoki J, Laaksoaho O, Pulliainen AT. Galectin-3-binding protein: a multitask glycoprotein with innate immunity functions in viral and bacterial infections. J Leukoc Biol. 2018;104(4):777&#x2013;786. doi: 10.1002/JLB.3VMR0118-036R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.3VMR0118-036R</ArticleId><ArticleId IdType="pubmed">29882603</ArticleId></ArticleIdList></Reference><Reference><Citation>Sindrewicz P, Yates EA, Turnbull JE, Lian LY, Yu LG. Interaction with the heparin-derived binding inhibitors destabilizes galectin-3 protein structure. Biochem Biophys Res Commun. 2020;523(2):336&#x2013;341. doi: 10.1016/j.bbrc.2019.12.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2019.12.054</ArticleId><ArticleId IdType="pubmed">31866013</ArticleId></ArticleIdList></Reference><Reference><Citation>Colomb F, Wang W, Simpson D, Zafar M, Beynon R, Rhodes JM, Yu LG. Galectin-3 interacts with the cell-surface glycoprotein CD146 (MCAM, MUC18) and induces secretion of metastasis-promoting cytokines from vascular endothelial cells. J Biol Chem. 2017;292(20):8381&#x2013;8389. doi: 10.1074/jbc.M117.783431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M117.783431</ArticleId><ArticleId IdType="pmc">PMC5437243</ArticleId><ArticleId IdType="pubmed">28364041</ArticleId></ArticleIdList></Reference><Reference><Citation>Peretz ASR, Rasmussen NS, Jacobsen S, Sj&#xf6;wall C, Nielsen CT. Galectin-3-binding protein is a novel predictor of venous thromboembolism in systemic lupus erythematosus. Clin Exp Rheumatol. 2021;39(6):1360&#x2013;1368. doi: 10.55563/clinexprheumatol/ol0vqj.</Citation><ArticleIdList><ArticleId IdType="doi">10.55563/clinexprheumatol/ol0vqj</ArticleId><ArticleId IdType="pubmed">33337998</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams JC. Thrombospondin-1. Int J Biochem Cell Biol. 1997;29(6):861&#x2013;865. doi: 10.1016/S1357-2725(96)00171-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1357-2725(96)00171-9</ArticleId><ArticleId IdType="pubmed">9304800</ArticleId></ArticleIdList></Reference><Reference><Citation>Aburima A, Berger M, Spurgeon BEJ, Webb BA, Wraith KS, Febbraio M, Poole AW, Naseem KM. Thrombospondin-1 promotes hemostasis through modulation of cAMP signaling in blood platelets. Blood. 2021;137(5):678&#x2013;689. doi: 10.1182/blood.2020005382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020005382</ArticleId><ArticleId IdType="pubmed">33538796</ArticleId></ArticleIdList></Reference><Reference><Citation>Patsouras M, Tsiki E, Karagianni P, Vlachoyiannopoulos PG. The role of thrombospondin-1 in the pathogenesis of antiphospholipid syndrome. J Autoimmun. 2020;115:102527. doi: 10.1016/j.jaut.2020.102527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102527</ArticleId><ArticleId IdType="pubmed">32709480</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#xf6;llmy F, van den Toorn H, Zenezini Chiozzi R, Zucchetti O, Papi A, Volta CA, Marracino L, Vieceli Dalla Sega F, Fortini F, Demichev V, et al. A serum proteome signature to predict mortality in severe COVID-19 patients. Life Sci Alliance. 2021;4(9):e202101099. doi: 10.26508/lsa.202101099.</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.202101099</ArticleId><ArticleId IdType="pmc">PMC8321673</ArticleId><ArticleId IdType="pubmed">34226277</ArticleId></ArticleIdList></Reference><Reference><Citation>Lourido L, Ayoglu B, Fern&#xe1;ndez-Tajes J, Oreiro N, Henjes F, Hellstr&#xf6;m C, Schwenk JM, Ruiz-Romero C, Nilsson P, Blanco FJ. Discovery of circulating proteins associated to knee radiographic osteoarthritis. Sci Rep. 2017;7(1):137. doi: 10.1038/s41598-017-00195-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-00195-8</ArticleId><ArticleId IdType="pmc">PMC5427840</ArticleId><ArticleId IdType="pubmed">28273936</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshihara Y, Plaas A, Osborn B, Margulis A, Nelson F, Stewart M, Rugg MS, Milner CM, Day AJ, Nemoto K, et al. Superficial zone chondrocytes in normal and osteoarthritic human articular cartilages synthesize novel truncated forms of inter-alpha-trypsin inhibitor heavy chains which are attached to a chondroitin sulfate proteoglycan other than bikunin. Osteoarthr Cartil. 2008;16(11):1343&#x2013;1355. doi: 10.1016/j.joca.2008.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joca.2008.04.004</ArticleId><ArticleId IdType="pubmed">18524635</ArticleId></ArticleIdList></Reference><Reference><Citation>Solmaz I, Kocak E, Kaplan O, Celebier M, Anlar B. Analysis of plasma protein biomarkers in childhood onset multiple sclerosis. J Neuroimmunol. 2020;348:577359. doi: 10.1016/j.jneuroim.2020.577359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2020.577359</ArticleId><ArticleId IdType="pubmed">32841722</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell DB, Heyden EL, Pretorius E. the biology of lactoferrin, an iron-binding protein that can help defend against viruses and bacteria. Front Immunol. 2020;11:1221. doi: 10.3389/fimmu.2020.01221.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01221</ArticleId><ArticleId IdType="pmc">PMC7271924</ArticleId><ArticleId IdType="pubmed">32574271</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Liao X, Song X, He M, Xiao F, Jin X, Xie X, Zhang Z, Wang B, Zhou C, et al. Severe adaptive immune suppression may be why patients with severe COVID-19 cannot be discharged from the ICU even after negative viral tests. Front Immunol. 2021;12:755579. doi: 10.3389/fimmu.2021.755579.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.755579</ArticleId><ArticleId IdType="pmc">PMC8640185</ArticleId><ArticleId IdType="pubmed">34867988</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada E, Itoh Y, Sitizyo K, Takeuchi T, Araki Y, Kitagawa H. Characteristic transport of lactoferrin from the intestinal lumen into the bile via the blood in piglets. Comp Biochem Physiol A Mol Integr Physiol. 1999;124(3):321&#x2013;327. doi: 10.1016/S1095-6433(99)00122-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1095-6433(99)00122-1</ArticleId><ArticleId IdType="pubmed">10665381</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuzaki T, Nakamura M, Nogita T, Sato A. Cellular uptake and release of intact lactoferrin and its derivatives in an intestinal enterocyte model of Caco-2 Cells. Biol Pharm Bull. 2019;42(6):989&#x2013;995. doi: 10.1248/bpb.b19-00011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.b19-00011</ArticleId><ArticleId IdType="pubmed">31155596</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang H, Judd RL. Adiponectin regulation and function. Compr Physiol. 2018;8(3):1031&#x2013;1063. doi: 10.1002/cphy.c170046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cphy.c170046</ArticleId><ArticleId IdType="pubmed">29978896</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer C, Hampartzoumian T, Lloyd A, Zekry A. A novel role for adiponectin in regulating the immune responses in chronic hepatitis C virus infection. Hepatology. 2008;48(2):374&#x2013;384. doi: 10.1002/hep.22387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.22387</ArticleId><ArticleId IdType="pubmed">18666256</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochepied T, Berger FG, Baumann H, Libert C. Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev. 2003;14(1):25&#x2013;34. doi: 10.1016/S1359-6101(02)00054-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1359-6101(02)00054-0</ArticleId><ArticleId IdType="pubmed">12485617</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceciliani F, Lecchi C. The immune functions of &#x3b1;(1) acid glycoprotein. Curr Protein Pept Sci. 2019;20(6):505&#x2013;524. doi: 10.2174/1389203720666190405101138.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389203720666190405101138</ArticleId><ArticleId IdType="pubmed">30950347</ArticleId></ArticleIdList></Reference><Reference><Citation>Barroso-Sousa R, Lobo RR, Mendon&#xe7;a PR, Mem&#xf3;ria RR, Spiller F, Cunha FQ, Pazin-Filho A. Decreased levels of alpha-1-acid glycoprotein are related to the mortality of septic patients in the emergency department. Clinics (Sao Paulo) 2013;68(8):1134&#x2013;1139. doi: 10.6061/clinics/2013(08)12.</Citation><ArticleIdList><ArticleId IdType="doi">10.6061/clinics/2013(08)12</ArticleId><ArticleId IdType="pmc">PMC3752623</ArticleId><ArticleId IdType="pubmed">24037010</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, Quan S, Zhang F, Sun R, Qian L, et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell. 2020;182(1):59&#x2013;72.e15. doi: 10.1016/j.cell.2020.05.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.032</ArticleId><ArticleId IdType="pmc">PMC7254001</ArticleId><ArticleId IdType="pubmed">32492406</ArticleId></ArticleIdList></Reference><Reference><Citation>Song JW, Lam SM, Fan X, Cao WJ, Wang SY, Tian H, Chua GH, Zhang C, Meng FP, Xu Z, et al. Omics-driven systems interrogation of metabolic dysregulation in COVID-19 pathogenesis. Cell Metab. 2020;32(2):188&#x2013;202.e185. doi: 10.1016/j.cmet.2020.06.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2020.06.016</ArticleId><ArticleId IdType="pmc">PMC7311890</ArticleId><ArticleId IdType="pubmed">32610096</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas T, Stefanoni D, Reisz JA, Nemkov T, Bertolone L, Francis RO, Hudson KE, Zimring JC, Hansen KC, Hod EA, Spitalnik SL, D'Alessandro A. COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. JCI Insight. 2020;5(14):e140327. 10.1172/jci.insight.140327. PMID: 32559180; PMCID: PMC7453907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7453907</ArticleId><ArticleId IdType="pubmed">32559180</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannun YA, Obeid LM. Sphingolipids and their metabolism in physiology and disease. Nat Rev Mol Cell Biol. 2018;19(3):175&#x2013;191. doi: 10.1038/nrm.2017.107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm.2017.107</ArticleId><ArticleId IdType="pmc">PMC5902181</ArticleId><ArticleId IdType="pubmed">29165427</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Shu T, Yang X, Song JX, Zhang M, Yao C, Liu W, Huang M, Yu Y, Yang Q, et al. Plasma metabolomic and lipidomic alterations associated with COVID-19. Natl Sci Rev. 2020;7(7):1157&#x2013;1168. doi: 10.1093/nsr/nwaa086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nsr/nwaa086</ArticleId><ArticleId IdType="pmc">PMC7197563</ArticleId><ArticleId IdType="pubmed">34676128</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyle JE, Burnum-Johnson KE, Wendler JP, Eisfeld AJ, Halfmann PJ, Watanabe T, Sahr F, Smith RD, Kawaoka Y, Waters KM, et al. Plasma lipidome reveals critical illness and recovery from human Ebola virus disease. Proc Natl Acad Sci U S A. 2019;116(9):3919&#x2013;3928. doi: 10.1073/pnas.1815356116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1815356116</ArticleId><ArticleId IdType="pmc">PMC6397561</ArticleId><ArticleId IdType="pubmed">30808769</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruzzone C, Bizkarguenaga M, Gil-Redondo R, Diercks T, Arana E, Garc&#xed;ade Vicu&#xf1;a A, Seco M, Bosch A, Palaz&#xf3;n A, San Juan I, et al. SARS-CoV-2 infection dysregulates the metabolomic and lipidomic profiles of serum. iScience. 2020;23(10):101645. doi: 10.1016/j.isci.2020.101645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2020.101645</ArticleId><ArticleId IdType="pmc">PMC7534591</ArticleId><ArticleId IdType="pubmed">33043283</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie S, Zhao X, Zhao K, Zhang Z, Zhang Z, Zhang Z: Metabolic disturbances and inflammatory dysfunction predict severity of coronavirus disease 2019 (COVID-19): a retrospective study. medRxiv. 2020:2020.2003.2024.20042283.</Citation></Reference><Reference><Citation>Casari I, Manfredi M, Metharom P, Falasca M. Dissecting lipid metabolism alterations in SARS-CoV-2. Prog Lipid Res. 2021;82:101092. doi: 10.1016/j.plipres.2021.101092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plipres.2021.101092</ArticleId><ArticleId IdType="pmc">PMC7869689</ArticleId><ArticleId IdType="pubmed">33571544</ArticleId></ArticleIdList></Reference><Reference><Citation>Das UN. Can bioactive lipids inactivate coronavirus (COVID-19)? Arch Med Res. 2020;51(3):282&#x2013;286. doi: 10.1016/j.arcmed.2020.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2020.03.004</ArticleId><ArticleId IdType="pmc">PMC7270578</ArticleId><ArticleId IdType="pubmed">32229155</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell DB, Pretorius E. The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications. Biochem J. 2022;479(16):1653&#x2013;1708. doi: 10.1042/BCJ20220154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20220154</ArticleId><ArticleId IdType="pmc">PMC9484810</ArticleId><ArticleId IdType="pubmed">36043493</ArticleId></ArticleIdList></Reference><Reference><Citation>Smatti MK, Cyprian FS, Nasrallah GK, Al Thani AA, Almishal RO, Yassine HM. Viruses and autoimmunity: a review on the potential interaction and molecular mechanisms. Viruses. 2019 doi: 10.3390/v11080762.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11080762</ArticleId><ArticleId IdType="pmc">PMC6723519</ArticleId><ArticleId IdType="pubmed">31430946</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas M, Rodr&#xed;guez Y, Acosta-Ampudia Y, Monsalve DM, Zhu C, Li QZ, Ram&#xed;rez-Santana C, Anaya JM. Autoimmunity is a hallmark of post-COVID syndrome. J Transl Med. 2022;20(1):129. doi: 10.1186/s12967-022-03328-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03328-4</ArticleId><ArticleId IdType="pmc">PMC8924736</ArticleId><ArticleId IdType="pubmed">35296346</ArticleId></ArticleIdList></Reference><Reference><Citation>Winchester N, Calabrese C, Calabrese LH. The intersection of COVID-19 and autoimmunity: what is our current understanding? Pathog Immun. 2021;6(1):31&#x2013;54. doi: 10.20411/pai.v6i1.417.</Citation><ArticleIdList><ArticleId IdType="doi">10.20411/pai.v6i1.417</ArticleId><ArticleId IdType="pmc">PMC8097827</ArticleId><ArticleId IdType="pubmed">33969248</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinz MM, Persson M, Aresh B, Olsson K, Cheng AJ, Ahlstrand E, Lilja M, Lundberg TR, Rullman E, M&#xf6;ller K&#xc4;, Sandor K, Ajeganova S, Yamada T, Beard N, Karlsson BC, Tavi P, Kenne E, Svensson CI, Rassier DE, Karlsson R, Friedman R, Gustafsson T, Lanner JT. Oxidative hotspots on actin promote skeletal muscle weakness in rheumatoid arthritis. JCI Insight. 2019;5(9):e126347. 10.1172/jci.insight.126347. PMID: 30920392; PMCID: PMC6538353.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6538353</ArticleId><ArticleId IdType="pubmed">30920392</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Ebinger JE, Mostafa R, Budde P, Gajewski J, Walker B, Joung S, Wu M, Br&#xe4;utigam M, Hesping F, et al. Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection. J Transl Med. 2021;19(1):524. doi: 10.1186/s12967-021-03184-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-021-03184-8</ArticleId><ArticleId IdType="pmc">PMC8716184</ArticleId><ArticleId IdType="pubmed">34965855</ArticleId></ArticleIdList></Reference><Reference><Citation>Charnley M, Islam S, Bindra GK, Engwirda J, Ratcliffe J, Zhou J, Mezzenga R, Hulett MD, Han K, Berryman JT, et al. Neurotoxic amyloidogenic peptides in the proteome of SARS-COV2: potential implications for neurological symptoms in COVID-19. Nat Commun. 2022;13(1):3387. doi: 10.1038/s41467-022-30932-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30932-1</ArticleId><ArticleId IdType="pmc">PMC9189797</ArticleId><ArticleId IdType="pubmed">35697699</ArticleId></ArticleIdList></Reference><Reference><Citation>Nystr&#xf6;m S, Hammarstr&#xf6;m P. Amyloidogenesis of SARS-CoV-2 spike protein. J Am Chem Soc. 2022;144(20):8945&#x2013;8950. doi: 10.1021/jacs.2c03925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jacs.2c03925</ArticleId><ArticleId IdType="pmc">PMC9136918</ArticleId><ArticleId IdType="pubmed">35579205</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A, Zlitni S, Brooks EF, Vance SE, Dahlen A, Hedlin H, Park RM, Han A, Schmidtke DT, Verma R, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med (N Y) 2022;3(6):371&#x2013;387.e379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascolini S, Vannini A, Deleonardi G, Ciordinik M, Sensoli A, Carletti I, Veronesi L, Ricci C, Pronesti A, Mazzanti L, et al. COVID-19 and immunological dysregulation: can autoantibodies be useful? Clin Transl Sci. 2021;14(2):502&#x2013;508. doi: 10.1111/cts.12908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12908</ArticleId><ArticleId IdType="pmc">PMC7536986</ArticleId><ArticleId IdType="pubmed">32989903</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M, Barman L, Bennett K, Chakraborty S, Chang I, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021;12(1):5417. doi: 10.1038/s41467-021-25509-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25509-3</ArticleId><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, Wood J, Jaycox J, Lu P, Dhodapkar RM, Gehlhausen JR, Tabachnikova A, Tabacof L, Malik AA, Kamath K et al. Distinguishing features of long COVID identified through immune profiling. medRxiv. 2022:2022.2008.2009.22278592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Chertow D, Stein, S., Ramelli, S. et al.: SARS-CoV-2 infection and persistence throughout the human body and brain. ResearchSquare 2021. 10.21203/rs.3.rs-1139035/v1.</Citation></Reference><Reference><Citation>Cheung CCL, Goh D, Lim X, Tien TZ, Lim JCT, Lee JN, Tan B, Tay ZEA, Wan WY, Chen EX, et al. Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. Gut. 2022;71(1):226&#x2013;229. doi: 10.1136/gutjnl-2021-324280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324280</ArticleId><ArticleId IdType="pubmed">34083386</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>